68
69
24) Perzanowski C, Osur M, Myrin B, Sehra R. Amiodarone does improve survival in out of hospital cardiac arrest in a rural and semi-rural setting. Europace, 4, Suppl. l, A24, 2003.
25) Skrifvars MB, Kuisma M, Boyd J, Määttä T, Repo J, Rosenberg PH, Castren M. The use of undiluted amiodarone in the management of out-of-hospital cardiac arrest. Acta.
Anaesthesiol. Scand., 48 (5), 582–587, 2004.
26) Pollak PT, Wee V, Al-Hazmi A, Martin J, Zarnke KB. The use of amiodarone for in-hospital cardiac arrest. Can. J. Cardiol., 22 (3), 199–202, 2006.
27) Rea RS, Kane-Gill SL, Rudis MI, Seybert AL, Oyen LJ, Ou NN, Stauss JL, Kirisci L, Idrees U, Henderson SO. Comparing intravenous amiodarone or lidocaine, or both, outcomes for inpatients with pulseless ventricular arrhythmias. Crit Care Med., 34 (6), 1617–1623, 2006.
28) Piccini JP, Schulte PJ, Pieper KS, Mehta RH, White HD, Van de Werf F, Ardissino D, Califf RM, Granger CB, Ohman EM, Alexander JH. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. Crit.Care Med., 39 (1), 78–83, doi: 10.1097/CCM.0b013e3181fd6ad7, 2011.
29) 久保貞裕, 服部友紀, 木村卓二, 南仁哲, 大野貴之, 三浦敏靖, 増田和彦, 谷内仁, 安藤雅樹, 竹内昭憲, 祖父江和哉. 心肺蘇生時のアミオダロン投与に関する当院で の現状. Prog Med., 31, Suppl. 1, 717-721, 2011.
30）渡邉絵里, 浅井琢美, 南健太郎, 中野浩, 浅岡峰雄, 院外発生難治性心室細動に対す
るアミオダロン静脈内投与の有効性の検討―蘇生率向上を目指して. Prog Med. 31, Suppl. 1, 709-712, 2011.
31) Huang CH, Yu PH, Tsai MS, Chang WT, Tang CH, Chen WJ. Amiodarone, lidocaine or neither for shockable cardiac arrest patients in emergency room – A nationwide cohort study.
Resuscitation, 96, Suppl. 1, 23-24,doi: org/10.1016/j.resuscitation.2015.09.054, 2015.
70
32) Kudenchuk PJ, Brown SP, Daya M, Rea T, Nichol G, Morrison LJ, Leroux B, Vaillancourt C, Wittwer L, Callaway CW, Christenson J, Egan D, Ornato JP, Weisfeldt ML, Stiell IG, Idris AH, Aufderheide TP, Dunford JV, Colella MR, Vilke GM, Brienza AM,
Desvigne-Nickens P, Gray PC, Gray R, Seals N, Straight R, Dorian P; Resuscitation Outcomes Consortium Investigators. Amiodarone. lidocaine, or placebo in out-of-hospital cardiac arrest. N Engl J Med., 374 (18), 1711–1722, doi: 10.1056/NEJMoa1514204, 2016.
33) 田原良雄, SOS-KANTO研究 (アミオダロン vs. ニフェカラント), 循環器内科, 68 (3), 253-261, 2010.
34) 伊藤博, 五十嵐正樹, 坪田貴也, 木内俊介, 藤井悠一郎, 吉原克則, 致死的不整脈 に対するニフェカラントおよびアミオダロン有効性の検討. 心臓, 42 , Suppl. 2, 78- 81, 2010.
35) Amino M, Inokuchi S, Nagao K, Nakagawa Y, Yoshioka K, Ikari Y, Funakoshi H, Hayakawa K, Matsuzaki M, Sakurai A, Tahara Y, Yonemoto N, Yaguchi A, Morimura N;
SOS-KANTO 2012 Study Group. Nifekalant hydrochloride and amiodarone hydrochloride result in similar improvement for 24-hour survival in cardiopulmonary arrest patients: the SOS-KANTO 2012 study. J Cardiovasc Pharmacol., 66(6), 600–609,doi:
10.1097/FJC.0000000000000310, 2015.
36) 網野真理, 吉岡公一郎, 岩田理, 藤倉寿則, 出口喜昭, 伴和信, 椎名豊, 後藤信哉, 半田俊之介, 田辺晃久, 中川儀英, 守田誠司, 岩瀬弘忠, 山本五十年, 猪口貞樹, 丸 谷喜紀. リドカイン抵抗性を示した難治性頻拍性心室不整脈に対するニフェカラン トの有効性: 院外心肺停止例における検討. J Cardiol., 41 (3), 127-134, 2003.
37) 五十嵐正樹, 豊田美和子, 宇野成明, 新居秀郎, 笹尾健一郎, 小澤司, 戸倉夏木, 三木義隆, 内野正文, 笹本修一, 本多満, 吉原克則, 小山信彌. 院外心室細動の
71
nifekalant静注による除細動効果. 心臓, 35, Suppl. 3, 99–103, 2003.
38) 清水敬樹, 杉田学, 黒木啓之, 横手龍, 三宅康史, 清田和也. 院外心肺停止患者に おける難治性心室細動に対するnifekalantの効果. 日集中医誌, 11, 105-110, 2004.
39) 五十嵐正樹, 徳安良紀, 堀進悟, 兼坂茂, 濱邊祐一, 三宅康史, 坂本哲也, 石松伸一, 斉藤大蔵, 田原良雄, 長尾健. 院外心室細動に対するNifekalant静脈内投与の有効 性に関する検討－SOS-KANTOによる調査. 日救急医会誌, 17, Suppl. 1, 340, 2006.
40) Ando J, Kakishita M, Sakai K, Komura Y, Nishiyama K, Iwabuchi M, Yokoi H, Yasumoto H, Nosaka H, Nobuyoshi M. Efficacy of nifekalant hydrochloride in the treatment of fatal ventricular arrhythmia in patients with ischemic heart disease. Int Heart J., 46 (4), 647–656, 2005.
41) Tahara Y, Kimura K, Kosuge M, Ebina T, Sumita S, Hibi K, Toyama H, Kosuge T, Moriwaki Y, Suzuki N, Sugiyama M, Umemura S. Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation. Circ J., 70 (4), 442–446, 2006.
42)Yoshioka K, Amino M, Morita S, Nakagawa Y, Usui K, Sugimoto A, Matsuzaki A, Deguchi Y, Yamamoto I, Inokuchi S, Ikari Y, Kodama I, Tanabe T. Can nifekalant hydrochloride be used as a first-line drug for Cardiopulmonary arrest (CPA)? - Comparative study of out-of-hospital CPA with acidosis and in-hospital CPA without acidosis -. Circ J., 70 (1), 21–27, 2006.
43) Shiga T, Tanaka K, Kato R, Amino M, Matsudo Y, Honda T, Sagara K, Takahashi A, Katoh T, Urashima M, Ogawa S, Takano T, Kasanuki H; Refractory VT/VF, Prospective
Evaluation to Differentiate Lidocaine Efficacy from Nifekalant (RELIEF) Study Investigators. Nifekalant versus lidocaine for in-hospital shock-resistant ventricular
fibrillation of tachycardia. Resuscitation, 81 (1), 47–52,doi:
72
10.1016/j.resuscitation.2009.09.027, 2010.44) 山嵜継敬, 高橋英雄, 津田泰任, 猪原実, 塗木裕也, 工藤真大, 村井治, 塚本喜昭, 大村延博. 致死的不整脈に対するニフェカラントおよびアミオダロン有効性の検討.
心臓, 42, Suppl. 4, 117–122, 2010.
45) Amino M, Yoshioka K, Opthof T, Morita S, Uemura S, Tamura K, Fukushima T, Higami S, Otsuka H, Akieda K, Shima M, Fujibayashi D, Hashida T, Inokuchi S, Kodama I, Tanabe T.
Comparative study of nifekalant versus amiodarone for shock-resistant ventricular
fibrillation in out-of hospital cardiopulmonary arrest patients. J Cardiovasc Pharmacol., 55 (4), 391–398, doi: 10.1097/FJC.0b013e3181d3dcc7, 2010.
46) 米良尚晃, 池田隆徳, 柚須悟, 阿部敦子, 石黒晴久, 塚田雄大, 宮越睦, 三輪陽介, 星田京子, 柳澤亮爾, 吉野秀朗. CCU管理を受けた心室頻拍・心室細動患者の臨床像 と静注用抗不整脈薬の使用実態および有効性. J Arrhythmia., 26, Suppl., 263, 2010.
47) 早川桂, 岡野尚弘, 矢野博子, 熊谷純一郎, 鈴木聖也, 勅使河原勝伸, 田口茂正, 横 手龍, 清田和也. 目撃ありの院外心肺停止に対するアミオダロン静注症例の検討.
Prog Med., 31, Suppl. 1, 722-726, 2011.
48) 山本真由美, 渡邉栄一, 市川智英, 針谷浩人, 祖父江嘉洋, 可児篤, 加藤千雄, 尾崎 行男. 当院の院外発生心肺停止蘇生例におけるアミオダロンとニフェカラントの効 果比較. J Arrhythmia., 28, Supp. l, 276, 2012.
49) Takenaka K, Niki S, Kurozumi Y, Yamamoto T, Yamauchi R, Yakenaka H, Haruna Y, Ozaki M, Kitaguchi S. Comparison of amiodarone and nifekalant for the treatment of cardiogenic shock patients with ventricular fibrillation. Circ J., 77, Suppl. 1, I-2070, 2013.
50) Harayama N, Nihei S, Nagata K, Isa Y, Goto K, Aibara K, Kamochi M, Sata T. Comparison of nifekalant and amiodarone for resuscitati out-of-hospital cardiopulmonary arrest resulting
73
from shock-resistant ventricular fibrillation. J Anesth., 28 (4), 587-592, doi:
10.1007/s00540-013-1775-5, 2014.
51) Tagami T, Matsui H, Ishinokami S, Oyanagi M, Kitahashi A, Fukuda R, Unemoto K, Fushimi K, Yasunaga H. Amiodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest. Resuscitation, 109,127-132, doi:
10.1016/j.resuscitation.2016.08.017, 2016.
52) Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. Cochrane Handbook for systematic Reviews of Interventions Version 5.1.0.
http://www.cochrane-handbook.org, 2011 (閲覧日: 2018年12月28日).
53) Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, Jang BH, Son HJ. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol., 66 (4), 408–414,doi: 10.1016/j.jclinepi.2012.09.016, 2013.
54) Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ., 315 (7109), 629-634, 1997.
55) 相原守夫. 診療ガイドラインのためのGRADEシステム 第2版. 凸版メディア株式 会社, 2015.
56) Marinelli A, Capucci A. Amiodarone (Nexterone) injection for the treatment and
prophylaxis of frequently recurring ventricular fibrillation. Expert Opin Pharmacother., 13 (4), 573–584, doi: 10.1517/14656566.2012.656589, 2012.
57) Gough WB, Zeiler RH, Barreca P, El-Sherif N, Hypotensive action of commercial
intravenous amiodarone and polysorbate 80 in dogs. J Cardiovasc Pharmacol., 4 (3), 375–
380, 1982.
74
58)Munoz A, Karila P, Gallay P, Zettelmeier F, Messner P, Mery M, Grolleau R. A
randomized hemodynamic comparison of intravenous amiodarone with and without Tween 80. European Heart Journal, 9 (2), 142-148, 1988.
59) Murakawa Y, Yamashita T, Kanese Y, Omata M. Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation?. JACC., 29 (3), 688-692, 1997.
60) Karlis G, Iacovidou N, Lelovas P, Niforopoulou P, Papalois A, Siafaka I, Mentzelopoulos S, Xanthos T. Nifekalant versus amiodarone in the treatment of cardiac arrest: an
experimental study in a swine model of prolonged ventricular fibrillation. Cardiovasc.
Drugs Ther., 29 (5), 425–431, 2015.
61) Ji XF, Li CS, Wang S, Yang L, Cong LH. Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest. Resuscitation, 81 (1), 1031-1036, doi:
10.1016/j.resuscitation.2010.04.023, 2010.
62) Karlsson V, Dankiewicz J, Nielsen N, Kern KB, Mooney MR, Riker RR, Rubertsson S, Seder DB, Stammet P, Sunde K, Søreide E, Unger BT, Friberg H. Association of gender to outcome after out-of-hospital cardiac arrest – a report from the International Cardiac Arrest Registry. Critical Care, 19, 182, doi: 10.1186/s13054-015-0904-y, 2015.
63)Niimura T, Zamami Y, Koyama T, Izawa-Ishizawa Y, Miyake M, Koga T, Harada K,
Ohshima A, Imai T, Kondo Y, Imanishi M, Takechi K, Fukushima K, Horinouchi Y, Ikeda Y, Fujino H, Tsuchiya K, Tamaki T, Hinotsu S, Kano MR, Ishizawa. Hydrocortisone
administration was associated with improved survival in Japanese patients with cardiac arrest. Sci Rep., 7 (1), 17919, doi:10.1038/s41598-017-17686-3, 2017.
64) Japan Medical Center. http://www.jmdc.co.jp/pharma/database.html, 2015 (閲覧日: 2018年